Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens

被引：1
|
作者：
Li, Zongru [1 ]
Ting, Zhao [1 ]
Hu, Lijuan [1 ]
Duan, Wenbing [2 ]
Jiang, Qian [2 ]
机构：
[1] Peking Univ, Peoples Hosp, Natl Clin Res Ctr Haematol Dis,Inst Haematol, Beijing Key Lab Haematopoiet Stem Cell Transplant, Beijing, Peoples R China
[2] Peking Univ, Peoples Hosp, Natl Clin Res Ctr Hematol Dis, Inst Hematol, Beijing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185471
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
    Jabbour, Elias
    Koller, Paul B.
    Oehler, Vivian G.
    Jamy, Omer H.
    Mukherjee, Sudipto
    Hunter, Anthony M.
    Baer, Maria R.
    Beck, Joseph T.
    Chen, Zi
    Guo, Huanshan
    Fu, Lei
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Kantarjian, Hagop
    Jiang, Lixin
    Wang, Cunlin
    BLOOD, 2022, 140
  • [2] Olverembatinib (HQP1351) Enhances Antitumor Effects of Chemotherapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
    Liang, Eric
    Min, Ping
    Xiong, Yan
    Wu, Bingxing
    Yu, Huidan
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2023, 142
  • [3] Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
    Jabbour, Panelelias
    Kantarjian, Hagop M.
    Koller, Paul B.
    Jamy, Omer
    Oehler, Vivian G.
    Lomaia, Elza
    Hunter, Anthony M.
    Uspenskaya, Olga
    Samarina, Svetlana
    Mukherjee, Sudipto
    Baer, Maria R.
    Zherebtsova, Vera
    Shuvaev, Vasily
    Turkina, Anna
    Davydkin, Igor
    Cortes, Jorge
    Guo, Huanshan
    Chen, Zi
    Fu, Lei
    Wang, Hengbang
    Jiang, Lixin
    Wang, Cunlin
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2023, 142
  • [4] Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/ Refractory Chronic Myeloid Leukemia (CML) and Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Jabbour, Elias
    Oehler, Vivian G.
    Koller, Paul B.
    Jamy, Omer
    Lomaia, Elza
    Hunter, Anthony M.
    Uspenskaya, Olga
    Samarina, Svetlana
    Mukherjee, Sudipto
    Cortes, Jorge E.
    Baer, Maria R.
    Zherebtsova, Vera
    Shuvaev, Vasily
    Turkina, Anna
    Davydkin, Igor
    Guo, Huanshan
    Chen, Zi
    Fu, Tommy
    Jiang, Lixin
    Wang, Cunlin
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S371 - S371
  • [5] Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study
    Wen, Ziyu
    Fan, Zhiping
    Wang, Qiang
    Zhou, Xuan
    He, Zherou
    Gao, Zicheng
    Chen, Hong
    Liang, Hanyin
    Luo, Dongmei
    Liu, Xiaoli
    Zhou, Hongsheng
    Liu, Qifa
    Xu, Na
    BLOOD, 2023, 142
  • [6] Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Jabbour, Elias J.
    Kantarjian, Hagop
    Issa, Ghayas C.
    Beck, Joseph Thaddeus
    Klisovic, Rebecca B.
    Mukherjee, Sudipto
    Oehler, Vivian G.
    Chen, Zi
    Lu, Ming
    Fu, Tommy
    Jiang, Lixin
    Zhai, Yifan
    Yang, Dajun
    BLOOD, 2021, 138
  • [7] Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH plus ) Chronic Myeloid Leukemia (CML) or PH plus Acute Lymphoblastic Leukemia (ALL): a Pharmacokinetic Study
    Hijiya, Nobuko
    Zwaan, C. Michel
    Rizzari, Carmelo
    Foa, Roberto
    Abbink, Floor
    Lancaster, Donna
    Landman-Parker, Judith
    Millot, Frederic
    Moppett, John
    Nelken, Brigitte
    Ducassou, Stephane
    Putti, Maria Caterina
    Tian, Xianbin
    Sinclair, Karen
    Santanastasio, Helene
    Buchbinder, Aby
    Kearns, Pamela
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S34 - S34
  • [8] LINEAGE INVOLVEMENT OF BCR-ABL IN PHILADELPHIA-CHROMOSOME-POSITIVE (PH+) LYMPHOBLASTIC MALIGNANCIES - CHRONIC MYELOGENOUS LEUKEMIA (CML) PRESENTING IN LYMPHOID BLAST PHASE (CML-LBP) VS PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    ANASTASI, J
    FENG, J
    LEBEAU, MM
    RUBIN, CM
    LARSON, RA
    ROWLEY, JD
    VARDIMAN, JW
    LABORATORY INVESTIGATION, 1995, 72 (01) : A105 - A105
  • [9] Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Cortes, Jorge
    Thomas, Deborah A.
    Faderl, Stefan
    Jones, Dan
    Jabbour, Elias
    Koller, Charles
    Dara, Samuel
    Garris, Rebecca
    Kebriaei, Partow
    Borthakur, Gautam
    Ferrajoli, Alessandra
    O'Brien, Susan
    BLOOD, 2009, 114 (22) : 806 - 807
  • [10] Dasatinib population pharmacokinetics in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ph plus all)
    Dai, Guowei
    Roy, Amit
    Mandava, Mohan
    Blackwood-Chirchir, Anne
    Luo, Roger
    Wu, Chiyuan
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1085 - 1085
12345